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ABSTRACT
Background. The addition of tubulointerstitial inflammation to the existing pathological classification of IgA nephropathy
(IgAN) is appealing but was previously precluded due to reportedly wide inter-observer variability. We report a novel
method to score percentage of non-atrophic renal cortex containing active tubulointerstitial inflammation (ATIN) in
patients with IgAN and assess its utility to predict clinical outcomes.
Methods. All adult patients with a native renal biopsy diagnosis of IgAN between 2010 and 2015 in a unit serving 1.5 million people
were identified. Baseline characteristics, biopsy reports and outcome data were collected. ATIN was calculated by subtracting the
percentage of atrophic cortex from the percentage of total cortex with tubulointerstitial inflammation, with10% representing
significant ATIN. The primary outcome was a composite of requiring renal replacement therapy or doubling of serum creatinine.
Results. In total 153 new cases of IgAN were identified, of which 111 were eligible for inclusion. Of these, 76 (68%) were male
and 54 (49%) had ATIN on biopsy. During a median follow-up of 2.3 years, 34 (31%) reached the primary outcome. On
univariable Cox regression analysis, ATIN was associated with a five-fold increase in the primary outcome [hazard ratio
(HR) (95% confidence interval) 4.9 (95% confidence interval (CI) 2.1–11.3)]. On multivariable analysis, mesangial
hypercellularity, tubular atrophy and interstitial fibrosis and ATIN independently associated with renal outcome (P¼0.02
for ATIN). Inter-observer reproducibility revealed fair agreement in the diagnosis of ATIN (j¼0.43, P¼0.05).
Conclusions. Within our centre, ATIN was significantly associated with renal outcome in patients with IgAN, independently
of established histological features and baseline clinical characteristics.
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INTRODUCTION
IgA nephropathy (IgAN) is the most common primary glomeru-
lonephritis worldwide [1]. Diagnosis is confirmed by the pres-
ence of IgA dominant or co-dominant immune deposits in
glomeruli on immunofluorescence or immunohistochemistry
[2]. The spectrum of histological and clinical disease is varied
but 25% progress to end-stage renal disease (ESRD) within
10 years of diagnosis [3]. Histological reporting of IgAN is now
standardized following publication of the Oxford Classification
of IgA Nephropathy in 2009 [2, 4]. This system was developed by
an international working group following rigorous examination
of commonly reported histological variables to identify those
with robust definitions, reliable inter-observer reproducibility
and without collinearity with other variables. Four histopatho-
logical features were ultimately included: mesangial hypercellu-
larity (M), endocapillary hypercellularity (E), segmental
glomerulosclerosis (S) and tubular atrophy and interstitial fibro-
sis (T). The ‘MEST’ classification system has subsequently been
validated in numerous cohorts [5–7] and has been shown to im-
prove significantly the prediction of renal outcomes in patients
with IgAN when combined with baseline clinical data [3]. The
original working group continue to refine and improve the path-
ological classification of IgAN with an update in 2016 announc-
ing the addition of crescents (C) to form the MEST-C score [7].
There are, however, limitations to the clinical application of
the MEST-C score: not all features are predictive of renal out-
come [5, 7, 8] and patients with Henoch–Schonlein purpura
(HSP), which is pathologically indistinguishable from IgAN on
biopsy, were excluded from validation studies. Furthermore, be-
yond prognostication of renal outcome, the role of the MEST-C
score in guiding management decisions has never been pro-
spectively established. Although it is unsurprising that markers
of chronic damage, such as tubular atrophy, interstitial fibrosis
and glomerulosclerosis, which are represented in the MEST
score as S and T, associate with a poor long-term renal outcome,
it is conceivable that the more active glomerular lesions, such
as M, E and C, may prove to be better predictors of response to
immunosuppressive therapy [4, 7, 9, 10]. Consequently, the ab-
sence of a measure of active tubulointerstitial inflammation
(ATIN) is a potential criticism of the current MEST-C score. In
this paper, we report a novel method to score the percentage of
renal cortex containing tubulointerstitial inflammation in
unscarred areas (ATIN) in patients with IgAN, similar to that
recorded in transplant biopsy reporting [11] and assess its abil-
ity to predict clinical outcomes when used in conjunction with
the established MEST-C score.
MATERIALS ANDMETHODS
Patient population
All adult patients with a first native renal biopsy diagnosis of
IgAN between 2010 and 2015 in the Glasgow Renal & Transplant
Unit were identified. This unit serves a defined population of 1.5
million, with the predominant ethnic group being white.
Baseline serum creatinine (sCr), serum albumin (sAlb) and urine
protein:creatinine ratio (uPCR) were recorded. Data from biopsy
reports were recorded including date of biopsy, number of glo-
meruli, number of globally sclerosed glomeruli, individual M, E,
S, T and C scores, and cumulative MEST-C score. Patients with
fewer than eight glomeruli on biopsy were excluded in line with
existing literature [2, 7]. In addition, patients with a T score of 2
were excluded on the basis that our method of scoring ATIN us-
ing an estimated percentage of viable cortex would be inappro-
priate and irrelevant in the presence of extensive tubular
atrophy. Clinical correspondence was reviewed to determine if
patients had a coexisting clinical diagnosis of HSP. Data were
collected regarding immunosuppressive therapy during follow-
up, date of doubling of sCr, date of first renal replacement ther-
apy (RRT) and date of death (where applicable). The primary
outcome was a composite of doubling of sCr or requiring RRT.
Pathological technique
ATIN was calculated by subtracting the percentage of cortex
with tubular atrophy from the percentage of total cortex with
tubulointerstitial inflammation in order to make an indirect as-
sessment of the percentage of renal cortex in the biopsy in
which there was inflammation in non-scarred areas (Figure 1).
A binary threshold of 10% was deemed to represent significant
ATIN (score of 0 or 1). Biopsies were reported by a single pathol-
ogist, but inter-observer reproducibility was assessed by selec-
tion of a random sample of 14 cases representing >10% of the
total cohort, which were rescored by a second independent pa-
thologist for percentage of renal cortex with tubular atrophy
and percentage of renal cortex with tubulointerstitial inflamma-
tion. Additional guidance with regard to the pathological criteria
used to define the presence or absence of tubular atrophy and
interstitial inflammation for the purposes of calculating ATIN is
included in Supplementary data, Table S1.
Statistical analysis
Descriptive statistics are reported as mean and SD or median and
interquartile range (IQR) for normally distributed and non-
parametric variables, respectively. Time from renal biopsy to the
primary composite outcome was analysed using Cox proportional
hazards model with censoring at time of death or last recorded
blood result. Baseline variables were entered into the multivari-
able analysis and excluded in a stepwise manner until only varia-
bles that retained independent statistical significance (P< 0.05)
remained. Overall model fit was assessed using binary logistic re-
gression with an increase in Nagelkerke’s R2 suggesting a better
model fit. The frequency of immunosuppression in those with
and without different clinical and pathological features was com-
pared using Pearson’s chi-squared test, Fisher’s exact test (when
expected cell count was <5), two-sample t-test or Mann–Whitney
U test as appropriate. Correlation between ATIN and other patho-
logical variables was assessed using Spearman’s rank correlation.
Inter-observer reproducibility was measured using (i) kappa statis-
tic (j) for ATIN and (ii) intraclass correlation co-efficient (ICC)
(two-way random) for scores of the percentage of cortex contain-
ing either inflammation or tubular atrophy [12]. All analyses were
performed using SPSS 22.0 (IBM, Armonk, NY, USA) and a conven-
tional significance level of <0.05 was used. Figures were generated
using SPSS 22.0 (IBM, NY), Microsoft PowerPointVR 2011 and GNU
Image Manipulation ProgrammeVC (version 2.10.4).
RESULTS
Demographics
A total of 153 new cases of biopsy-proven IgAN were identified
over 6 years. Of these, 42 cases were excluded: 24 had fewer
than eight glomeruli on biopsy, 6 had inadequate biopsy for
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MEST scoring, 3 were on RRT at the time of biopsy and 9
patients had a T score of 2. Of the remaining 111 patients, 76
(68%) were male. Mean age at biopsy was 52 years (616.7) and 18
(16%) had a coexisting clinical diagnosis of HSP. Median sCr was
156 mmol/L (IQR 103–214) and median uPCR 228 mg/mmol (125–
435). 54 (49%) had ATIN on biopsy (Table 1). All patients were
managed to established blood pressure targets [13] and with
maximal dosing of inhibitors of the renin–angiotensin system,
where possible.
Outcomes
During a median follow-up of 2.3 years, 34 (31%) patients
reached the primary outcome and 16 (14%) died. Of those that
died nine reached the primary outcome prior to death. Cause of
death was cancer (n¼ 5), sepsis (n¼ 3), ESRD (n¼ 3), myocardial
infarction (n¼ 2), other (n¼ 2) and no data available (n¼ 1).
Univariable analysis
On univariable cox regression survival analysis, pathological
features that associated with the primary outcome included
MEST (cumulative), M, E, T, C and ATIN (Table 2). M and ATIN
had the greatest individual predictive impact and were associ-
ated with a near five-fold increase in the primary outcome [haz-
ard ratio (HR) (95% CI) 4.8 (95% CI 2.0–11.7) and 4.9 (95% CI 2.1–
11.3), respectively] (Figure 2). When compared with established
pathological variables, ATIN significantly correlated with M, T
and C. The strength of the correlation was comparable with that
seen between M and C (Supplementary data, Table S2). Clinical
features that were predictive of outcome included baseline sCr
and uPCR >100 mg/mmol (Table 2). There was an inverse rela-
tionship between sAlb and the primary outcome (Table 2).
Table 1. Baseline demographics in entire cohort and then sub-
divided based on whether or not patients had 10% ATIN
Variable
All
(n¼ 111)
No ATIN
(n¼ 57 )
ATIN
(n¼ 54) P
Male (%) 76 (68) 35 (61) 41 (76) 0.1
Mean age,
years (6SD)
52 (617) 49 (616) 55 (617) 0.056
HSP (%) 18 (16) 7 (12) 11 (20) 0.25
Median sCr,
umol/L (IQR)
156 (101–212) 122 (78–187) 165 (133–225) 0.002
uPCR, mg/mmol
(IQR)
228 (125–435) 184 (89–288) 340 (180–635) <0.001
M1 (%) 59 (53) 21 (37) 38 (70) <0.001
E1 (%) 70 (63) 31 (54) 39 (72) 0.052
S1 (%) 73 (66) 39 (68) 34 (63) 0.545
T1 (%) 24 (22) 8 (14) 16 (30) 0.046
C1 (%) 31 (28) 11 (19) 20 (37) <0.001
C2 (%) 9 (8) 0 (0) 9 (17) <0.001
ATIN (%) 54 (49%) – –
P-values relate to Pearson’s chi-squared test comparing frequencies based on
presence or absence of ATIN, except for age where a two-sample t-test was
used, and sCr and uPCR, where Mann–Whitney U tests were performed.
Accepted significance level for all variables defined as <0.05.
uPCR, urine protein:creatinine ratio at time of biopsy; M1, mesangial hypercellu-
larity in <50% of glomeruli; E1, presence of endocapillary hypercellularity; S1,
presence of segmental glomerulosclerosis; T1, tubular atrophy and interstitial fi-
brosis in 25–50% of cortex; T2, tubular atrophy and interstitial fibrosis in >50% of
cortex (excluded); C1, presence of active crescents in 1–25% of glomeruli; C2,
presence of active crescents in >25% of glomeruli; ATIN, presence of 10% of
non-scarred cortex containing active tubulointerstitial inflammation.
FIGURE 1: Diagrammatic representation of the pathological technique for calculating ATIN. (A) shows a low-powered magnification of a section of renal cortex with
areas delineated based on the presence or absence of tubular atrophy. (B), (C) and (D) all show a higher power magnification of the same tissue. To score ATIN, the pa-
thologist first makes an estimation of the total percentage of cortex in which inflammation is present as outlined by the yellow box of panel (B). Next, the pathologist
estimates of the percentage of cortex in which there is tubular atrophy as depicted by the black border in panel (C). Finally, the pathologist subtracts these two percen-
tages to produce a surrogate measure of the percentage of non-atrophic cortex in which tubulointersitial inflammation exists as depicted by the asterisks in panel (D).
This method is based on the assumption that areas of tubular atrophy and interstitial fibrosis will contain inflammation.
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Multivariable analysis
On multivariable analysis of pathological features, M, T and
ATIN independently contributed to the prediction model of re-
nal outcome whereas E, S and C did not (Table 3). When baseline
sCr (continuous), baseline sCr>150 (binary) or uPCR>100 were
added to the model, ATIN retained independent significance,
but the clinical parameters themselves did not. Overall model
fit improved with the addition of ATIN to M and T, with R2 in-
creasing from 0.29 to 0.37.
ATIN and response to immunosuppression
A total of 20 (18%) patients received immunosuppression, all of
which were steroid-based regimens (prednisolone 1 mg/kg, me-
dian dose 60 mg and median duration 7 months). Only six
patients received additional induction with oral cyclophospha-
mide (1.5–2 mg/kg/day, duration 3 months), of whom four
patients progressed to maintenance azathioprine therapy.
Baseline variables that associated with an increased frequency
of immunosuppression usage included M, E, C, ATIN, sCr, uPCR
and a clinical diagnosis of HSP (Supplementary data, Table S3).
Patients who received immunosuppression had a more severe
clinical phenotype as evidenced by higher sCr and uPCR at base-
line (Supplementary data, Table S3). Out of 20 patients, 18
patients received immunosuppression had ATIN on biopsy, of
whom 9 reached the primary outcome and 9 did not (Figure 3).
Conversely, 36 patients with ATIN did not receive immunosup-
pression of whom 18 reached the primary outcome and 18 did
not. On subgroup analysis of the 91 patients who did not receive
immunosuppression, M, T and ATIN all remained independent
predictors on multivariable analysis (data not shown).
Impact of HSP
Excluding the 18 patients with a coexistent clinical diagnosis of
HSP did not change the variables with independent predictive
significance on multivariable analysis. No pathological variable
was predictive of outcome in the 18 patients with HSP on uni-
variable or multivariable analysis (data not shown), although
these patients were more likely to receive immunosuppression
(Supplementary data, Table S3).
Inter-observer reproducibility
The reliability between the two raters in scoring the percentage
of cortex containing tubular atrophy and interstitial inflamma-
tion was ‘good’ (ICC 0.88; P¼ 0.001) and ‘excellent’ (ICC 0.91;
P< 0.001), respectively. Inter-observer reproducibility for the
FIGURE 2: Kaplan–Meier survival curve showing time until primary composite
outcome (doubling of sCr or RRT) based on the presence or absence of ATIN on
renal biopsy. Patients without events were censored at time of death or last
recorded blood result.
Table 2. HR for primary composite outcome (doubling of sCr or RRT)
based on a 1-unit increment in each individual pathological or bio-
chemical variable
Variable HR 95% CI P
M 4.8 2.0–11.7 <0.001
E 2.5 1.1–5.8 0.03
S 1.6 0.7–3.6 0.24
T 2.6 1.3–5.3 <0.001
C 1.9 1.2–3.1 0.007
MEST-C 1.9 1.5–2.5 <0.001
ATIN 4.9 2.1–11.3 <0.001
Baseline sCr (mmol/L) 1.004 1.001–1.006 0.008
uPCR 100 mg/mmol 4.9 1.2–20.4 0.03
sAlb (g/dL) 0.9 0.9–1.0 0.006
Cox proportional hazards model with accepted significance level of <0.05.
95% CI, 95% confidence interval; M, mesangial hypercellularity; E, endocapillary
hypercellularity; S, segmental glomerulosclerosis; T, tubular atrophy and inter-
stitial fibrosis; C, crescents, ordinal variable based on percentage of glomeruli
containing crescents (C0 ¼ 0%, C1 ¼ 125%, C2 ¼ >25%); MEST-C, cumulative of
M, E, S, T, C; ATIN, presence of 10% of non-scarred cortex containing active
tubulointerstitial inflammation; baseline sCr, serum creatinine at time of bi-
opsy; sAlb, serum albumin at time of biopsy.
Table 3. HRs for primary composite outcome (doubling of sCr or RRT)
based on multivariable analysis including all significant pathologi-
cal variables—only significant variables reported (A). Multivariable
model of independently significant pathological features, with the
addition of univariable significant baseline clinical parameters (B)
(A)
Variables in analysis HR 95% CI P
M 3.4 1.3–8.7 0.02
T 2.4 1.2–4.8 0.02
ATIN (binary) 3.0 1.2–7.4 0.02
(B)
Variables in analysis HR 95% CI P
M 3.3 1.3–8.1 0.02
T 1.9 0.9–4.1 NS
ATIN (binary) 2.6 1.0–6.3 0.04
Baseline sCr (mmol/L) 1.002 0.999–1.005 NS
uPCR 100 mg/mmol 2.7 0.6–11.5 NS
Cox proportional hazards model with accepted significance level of <0.05.
95% CI, 95% confidence interval; M, mesangial hypercellularity; T, tubular atro-
phy and interstitial fibrosis; ATIN (binary), presence of 10% of non-scarred cor-
tex containing active tubulointerstitial inflammation; baseline sCr, serum
creatinine at time of biopsy; NS, non-significant.
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diagnosis of ATIN was assessed by kappa statistic and revealed
a ‘fair’ agreement (j¼0.43, P¼ 0.05).
DISCUSSION
Our data show that the presence of >10% active tubulointersti-
tial nephritis within the viable cortex in patients with IgA ne-
phropathy was independently associated with renal outcome
and performed equivalent to, or better than, established MEST-
C variables. Further study is required to assess the plausible role
of ATIN in predicting response to immunosuppression in IgA
nephropathy.
The Oxford Classification of IgA Nephropathy [4] was a sig-
nificant step forward in providing a framework to diagnose a di-
verse pathological condition and, commendably, the authors
continue to evolve and improve it [7]. An assessment of tubu-
lointerstitial inflammation would be an appealing addition to
the current scoring system. Myllyma¨ki et al. found parameters
of tubulointerstitial inflammation predicted deterioration in re-
nal function in 204 patients with IgA nephropathy [14]. They
found significant interstitial inflammation in 25% of biopsies
and the grade of interstitial inflammation (normal, mild or
marked) correlated with disease progression. Similarly, Freese
et al. evaluated 67 biopsies from native kidneys of subsequent
kidney transplant patients whose primary diagnosis was IgA
nephropathy [15]. Cellular infiltrates in the interstitium were
more common in their study group of patients and they were
associated with shorter progression to ESRD. However, in both
studies the authors did not specify if the interstitial inflamma-
tion recorded was present in non-fibrotic interstitium, in fi-
brotic interstitium or both. Interstitial inflammation was
considered for the Oxford classification system but was ex-
cluded on the basis that the percentage of the total cortex with
interstitial inflammation correlated too closely with the degree
of interstitial fibrosis (r¼ 0.9), whereas the assessment of intersti-
tial inflammation in non-atrophic areas displayed unacceptably
poor ICC at only 0.03 [2]. Our technique overcomes both of these
problems. First, by focussing on the percentage of inflammation
in non-atrophic cortex we overcome the correlation with inter-
stitial fibrosis. Secondly, the two surrogate histological data
items that we use to calculate ATIN displayed acceptable ICC in
the original Oxford paper with tubular atrophy scoring 0.79 and
total interstitial inflammation at 0.58. This is confirmed on our
intra-cohort validation, with ‘fair’ inter-observer reproducibility
as assessed by kappa statistic.
ATIN does exhibit significant correlations with some of the
existing pathological variables; however, the strongest of these
correlations at r¼ 0.39 is well below the previously defined
threshold of r¼ 0.8 [4]. Furthermore, the independent signifi-
cance of ATIN was maintained in the multivariable analysis
with an 8% improvement in overall model fit as represented by
R2 rising from 0.29 to 0.37. This implies that 63% of the variation
in outcome is still unexplained by our model. Nevertheless, our
results are comparable with previous reports: validation of
MEST in the VALIGA cohort had a maximum R2 of 0.19 [3].
Patients with ATIN had a higher sCr and uPCR at baseline
(Table 1), however, ATIN maintained independent significance
even when these factors were adjusted for (Table 3).
Following recent randomized trials, the role of immunosup-
pression for the treatment of IgAN remains uncertain. There
remains some signal that immunosuppression may be benefi-
cial, for instance, proteinuria reduced in STOP-IgA [16] and renal
outcomes improved in TESTING [17], but these minor benefits
are outweighed by more significant risks for the majority of
patients. IgAN is a heterogeneous disease with variable clinical
phenotype. Given the robust pathological classification of IgAN
as a result of the Oxford classification system, it is disappoint-
ing that current trials have not stratified patients on this basis
and future trials would benefit from doing so. There is plausibil-
ity that ATIN could be a useful addition in this regard; however,
the numbers were too small in this study to address this, with
only 20 patients receiving immunosuppression of which 18 had
ATIN. That said, given that patients who received
FIGURE 3: Flow chart showing the number of patients who reached the primary outcome based on the presence or absence of ATIN and immunosuppression. Patients
who received immunosuppression had a more severe clinical phenotype, with higher sCr and proteinuria at baseline (Table 1).
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immunosuppression had a more severe clinical phenotype, the
fact that 50% of the ATIN group reached the primary outcome
regardless of immunosuppression or not, means that immuno-
suppression may have attenuated the primary outcome rates in
the more severe group. Further research in larger cohorts is re-
quired. Similarly, we intend to examine the relationship be-
tween immunosuppression and ATIN as an ordinal variable,
with a score of <10%, 10–24% and 25% corresponding to ATIN
values of 0, 1 and 2, respectively, in future studies in larger
cohorts.
There are limitations to this study, primarily that it is a ret-
rospective series from a single centre and requires validation.
There is wide variation in the incidence of biopsy-proven IgAN,
attributed to varying clinical practices with regard to the indica-
tion for biopsy. We have previously reported our results in com-
parison to other centres and found that our biopsy rate (and our
rate of IgAN diagnosis) lies within the middle of the range com-
pared with 10 countries worldwide [18]. The rates of immuno-
suppression within our cohort are lower than previously
reported [19], and the regimens used were not standardized,
meaning any confounding influence is likely to be non-uniform.
A single pathologist scored ATIN; however, assessment of inter-
observer reproducibility was found to be acceptable and we are
reassured by acceptable reproducibility of other scores that rely
on similar estimations of inflammation, such as the Banff crite-
ria for reporting renal transplant biopsies [20]. Further research
is required to test more rigorously the inter-observer reproduc-
ibility of ATIN. Aside from our novel reporting of ATIN, our
results are consistent with previous reports validating MEST in
clinical cohorts suggesting a reliability to our data. Consistent
with previous reports we found M, T and C to associate with re-
nal outcome [4, 5, 7]. E is variably reported to associate with re-
nal outcome in the absence of immunosuppression [5], and so
the weak association we observe may be explained by the lower
prevalence of immunosuppression in our cohort [7, 9]. In con-
trast to other reports [4, 7, 8, 21], S did not associate with renal
outcome within our cohort; however, this observation is by no
means unique [9, 22, 23]. The role of HSP remains to be clarified
but we believe there is value in including these patients in stud-
ies which examine an indistinguishable histological appear-
ance. The Oxford Classification of IgAN has previously been
shown to predict renal outcome in patients with HSP [24].
Furthermore, amongst patients with HSP who undergo renal bi-
opsy, renal outcome is similar to IgAN with 11–25% of patients
reaching ESRD within 10 years [25–27]. The exclusion of patients
with T2 has a minimal impact on the generalizability of our
results as it represented <6% of our biopsy population, with
similar figures reported previously [4]. A total of 16 patients died
during follow-up, but only 7 did so prior to reaching the primary
outcome and so death is unlikely to represent a significant com-
peting risk.
Our method for scoring ATIN relies on the assumption that
areas of tubular atrophy and interstitial fibrosis will always con-
tain inflammation. This assumption is contested in transplant
literature where differentiating bland, versus inflamed, areas of
fibrosis have prognostic significance [28, 29]. However, our as-
sumption remains valid in the majority of cases, with one study
showing only 65 out of 337 biopsies had no inflammation in
fibrotic areas [28]. Furthermore, in the original Oxford paper, in-
terstitial fibrosis and interstitial inflammation had a correlation
coefficient of 0.90, which was deemed ‘so close to 1 that to
include both in a classification would provide no additional
value’ [2].
In conclusion, within our centre ATIN was significantly asso-
ciated with renal outcome in patients with IgAN, independently
of established histological features and baseline clinical charac-
teristics. Further assessment of inter-observer reproducibility
and validation in other cohorts is still required but these results
suggest our method of assessing ATIN could be a worthwhile
addition to current pathological scoring systems for IgAN.
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